Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
GP-39 CRISPR/Cas9 KO Plasmid (h): sc-402147
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GP-39 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GP-39 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: GP-39 Antibody (D-11): sc-393494
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GP-39 CRISPR/Cas9 KO Plasmid (h) | sc-402147 | 20 µg | $397.00 |
Overview
CHI3L1 encodes GP-39 (YKL-40), a secreted glycoprotein of the chitinase-like family that lacks enzymatic activity but modulates extracellular matrix organization, cell adhesion, and tissue remodeling. GP-39 is produced by multiple cell types including macrophages, neutrophils, and fibroblast-like cells, and is linked to inflammatory signaling and stromal–immune interactions. It is implicated in regulation of angiogenic and fibrotic processes and is frequently studied in contexts involving chronic inflammation and aberrant matrix turnover. Dysregulated CHI3L1 expression has been associated with diverse disease-relevant phenotypes, including cancer-associated stroma, neuroinflammation, and metabolic and airway inflammatory states, making it a useful node for pathway and biomarker-mechanism research.
GP-39 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CHI3L1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CHI3L1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CHI3L1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GP-39 protein expression.
This CRISPR knockout system enables efficient generation of CHI3L1-deficient cell models for investigation of GP-39 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CHI3L1 exon(s) critical for GP-39 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CHI3L1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GP-39 CRISPR/Cas9 KO Plasmid (h) and GP-39 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CHI3L1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GP-39 HDR Plasmid (h) and GP-39 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CHI3L1 homology arms to support homology-directed repair at defined CHI3L1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.